Heron Therapeutics stock sits 77.22 percent below its 52-week high
Published on 10/17/2026 at 20:47 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWSMarket position and upcoming results
- The Nasdaq quote stood 77.22 percent below the 52-week high on October 16, 2026.
- Q3 2026 consensus revenue is USD 37.50 million.
- Heron Therapeutics stock was last at USD 0.36 on Nasdaq on October 16, 2026 at 4:00 p.m. ET, down 4.12 percent versus the prior close.
- Heron Therapeutics had a market capitalization of USD 68.5 million on October 16, 2026.
Heron Therapeutics (ISIN US4277461020) was last at USD 0.36 on Nasdaq on October 16, 2026 at 4:00 p.m. ET, 77.22 percent below its 52-week high of USD 1.58. The stock's latest placement gives investors a clear measure of the distance to its yearly peak. The next scheduled earnings report is set for November 3, 2026, with consensus revenue of USD 37.50 million, according to MarketBeat.
November 3 revenue estimate
The upcoming report is expected to provide the next quantified test for Heron's commercial portfolio. MarketBeat lists consensus earnings per share of minus USD 0.03 and revenue of USD 37.50 million for the third quarter of 2026. The same page gives prior-year revenue of USD 38.21 million, implying a comparison that remains centered on sales execution rather than a return to profitability.
Price sits below yearly high
Heron Therapeutics traded at USD 0.36 on October 16, 2026, down 4.12 percent from the prior Nasdaq close. Volume reached 1,725,606 shares, compared with an average of 2,428,978 shares, while the 52-week range extended from USD 0.26 to USD 1.58. The current quote was therefore 38.46 percent above the yearly low and 77.22 percent below the yearly high.
Valuation and upcoming date
Market capitalization stood at USD 68.5 million on October 16, 2026. The trailing price-to-earnings ratio was minus 1.90, while the dividend yield was 0.00 percent. The November 3 reporting date is described by MarketBeat as an estimated premarket announcement with an 8:30 a.m. ET conference call.
Comparison with peers
HRTX: minus 4.12 percent, P/E minus 1.90, market capitalization USD 68.5 million
Keros Therapeutics (NASDAQ, USD): minus 3.96 percent, P/E minus 3.31, market capitalization USD 211.4 million
Collegium Pharmaceutical (NASDAQ, USD): plus 0.04 percent, P/E 18.70, market capitalization USD 755.0 million
What the price position says
The comparison places Heron in a small-cap biotechnology group with sharply different profitability profiles. Keros Therapeutics had a similar negative daily move, while Collegium Pharmaceutical traded with a positive 0.04 percent change and a positive trailing P/E ratio. Heron's next scheduled report provides the next dated point for assessing whether revenue can approach the USD 37.50 million consensus estimate.
Heron Therapeutics was last at USD 0.36 on Nasdaq on October 16, 2026 at 4:00 p.m. ET, down 4.12 percent versus the prior close.
Market context: Market report Nasdaq Composite.
